02 · Clinical Findings
Los medicamentos GLP-1 pueden ayudar a revertir la prediabetes, según un estudio
A medical-record review in adults with obesity and prediabetes also linked GLP-1 drugs to a 31% lower risk of type 2 diabetes than metformin.

Could GLP-1 drugs help turn back prediabetes? A medical-record review linked them to better outcomes than metformin in adults with obesity and prediabetes.
Those receiving GLP-1 drugs were 53% more likely to regain normal blood sugar and had a 31% lower risk of developing type 2 diabetes.
The findings are due for presentation at an AHA meeting. Researchers emphasized that diet and exercise remain essential, while metformin remains a first-line option.
Read the full story at Infobae Salud ↗
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit

At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes

Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years

Continue reading · Clinical FindingsPeptide News / Clinical FindingsMenopausal Hormone Therapy May Boost GLP-1 Weight LossMedPage Today · Oct 27, 2026 · scroll to read